Sort   by:  
 Page size 
In castration-resistant prostate cancer (CRPC), clinical response to androgen receptor (AR) antagonists is limited mainly due to AR-variants expression and restored AR signaling. The metabolite spermine is most abundant in prostate and it decreases as prostate cancer progresses, but its functions re...
2023-10-11 | MTBLS8034 | MetaboLights
Sort   by:  
 Page size